2025 News

NCI Is Testing if the Merger of Recent Therapeutic Advances Improves Progression-Free and Overall Survival in Locally Advanced Cervical Cancer

• December 22, 2025

NCI-led Studies Crucial for FDA Approval of Selumetinib for Adults with Neurofibromatosis Type 1 (NF1) with Symptomatic Inoperable Plexiform Neurofibromas (PN) Diseases

• December 10, 2025

Proteomic Analysis of Clinical Trial Samples Uncovers Mechanism of Drug Resistance

• December 5, 2025

DCTD’s Translational Research Program Announces Fiscal Year 2025 SPORE Grantees

• November 26, 2025

Initial Results and Trials in Process - NCI MyeloMATCH Presentations at ASH 2025

• November 24, 2025

Introducing: Proteomic Data Commons 2.0

• November 20, 2025

Paulovich Laboratory at Fred Hutch Earns CAP Accreditation

• September 26, 2025

Featuring CPTAC Investigators: Marcin Cieslik

• September 4, 2025

In Memoriam: Former NCI Branch Chief, Dr. Gordon Cragg

• August 29, 2025

Proteogenomic Analysis of Clinical Trial Samples Identifies New Biomarkers

• August 26, 2025

National Cancer Institute’s Virtual Clinical Trials Office Gains Traction

• August 15, 2025

Global Multiomics Study Reveals Key Lung Cancer Markers and Targets

• August 7, 2025

Proteomics Measures Cancer Stemness and Identifies Therapeutic Targets

• May 29, 2025

Advancing Precision Medicine Through Spatial Cancer Profiling

• April 18, 2025

Advancing Multiple Myeloma Research with Kiran Kumar Mangalaparthi, Ph.D.

• March 26, 2025

Multiomics2Targets: Bridging Data and Discovery

• March 10, 2025